CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Generation and Functional Verification of Hypoxia-sensitive Chimeric Antigen Receptor-T Cells.
Generation and Functional Verification of Hypoxia-sensitive Chimeric Antigen Receptor-T Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 治疗血液肿瘤已显示显著前景,但实体瘤治疗仍面临挑战,例如CAR-T 攻击表达靶抗原的正常细胞所致的安全风险。为提高肿瘤选择性,研究者开发了缺氧敏感型CAR-T:将氧依赖性降解结构域融合至CAR,使其仅在肿瘤微环境等缺氧环境中高表达。本研究提供了这类CAR-T 的制备及功能表征方案,包括利用移动培养舱改变氧水平后分析CAR表达和杀伤能力。预期该细胞可依氧水平调节CAR表达及细胞毒性,从而区分缺氧肿瘤微环境与正常含氧组织,实现选择性活化。
Extensive studies have proven the promise of chimeric antigen receptor T (CAR-T) cell therapy in treating hematological malignancies.
However, treating solid tumors remains challenging, as exemplified by the safety concerns that arise when CAR-T cells attack normal cells expressing the target antigens. Researchers have explored various approaches to enhance the tumor selectivity of CAR-T cell therapy. One representative strategy along this line is the construction of hypoxia-sensitive CAR-T cells, which are designed by fusing an oxygen-dependent degradation domain to the CAR moiety and are strategized to attain high CAR expression only in a hypoxic environment-the tumor microenvironment (TME).
This paper presents a protocol for the generation of such CAR-T cells and their functional characterization, including methods to analyze the changes in CAR expression and killing capacity in response to different oxygen levels established by a mobile incubator chamber. The constructed CAR-T cells are anticipated to demonstrate CAR expression and cytotoxicity in an oxygen-sensitive manner, thus supporting their capability to distinguish between hypoxic TME and normoxic normal tissues for selective activation.
MEMBER ACCOUNT
登录成功会直接打开下一页。